Publications de Jérôme Barge

Correlations between photoactivable porphyrins’ fluorescence, erythema and the pain induced by PDT on normal skin using ALA-derivatives

Hubert van den Bergh, Georges Wagnières, Matthieu Philippe Emmanuel Zellweger, Jérôme Barge

Summary Background Photodynamic therapy (PDT) with precursors of photoactivable porphyrins is a well-established treatment modality for skin pathologies as well as hair removal. Pain is a major side effect thereof, and it affects the treatment compliance a ...

Elsevier2013

Correlation between Protoporphyrin IX Fluorescence Intensity, Photobleaching, Pain and Clinical Outcome of Actinic Keratosis Treated by Photodynamic Therapy

Hubert van den Bergh, Georges Wagnières, Matthieu Philippe Emmanuel Zellweger, Jérôme Barge, Filippo Piffaretti

Background: Photodynamic therapy (PDT) with Metvix® is a good therapeutic option to treat actinic keratosis, but it presents drawbacks (pain, lesion recurrences, heterogeneous outcome), emphasizing the possible need to individualize treatment. Objective: W ...

Karger2013

Chitosan-based nanogels for selective delivery of photosensitizers to macrophages and improved retention in and therapy of articular joints

Georges Wagnières, Jutta Christine Wandrey, Frédéric Schmitt, Jérôme Barge, Lucienne Lagopoulos

Macrophages play key roles in inflammatory disorders. Therefore, they are targets of treatments aiming at their local destruction in inflammation sites. However, injection of low molecular mass therapeutics, including photosensitizers, in inflamed joints r ...

Elsevier2010

Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer

Georges Wagnières, Frédéric Schmitt, Jérôme Barge

Aliphatic and ethylene glycol esters of 5-aminolevulinic acid (ALA) are very efficient precursors of the photosensitizer protoporphyrin IX (PpIX) for photodynamic therapy; however, they diffuse passively across the cell membrane and thus lack cell selectiv ...

American Chemical Society2008